NEW YORK, NY, USA I 03, 2025 I Pfizer Inc. (NYSE: PFE) today announced positive topline results from the progression-free survival (PFS) analysis of ...

This study will evaluate HCW9302 in patients with moderate to severe alopecia areata. MIRAMAR, FL, USA I 03, 2025 I HCW Biologics Inc. (“HCWB” or the “Company”) ( ...

New at-home RSV treatment represents a potential breakthrough in addressing the burden of respiratory diseases, especially in vulnerable pediatric and elderly ...

Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway to demonstrate cardiovascular benefits in a Phase III study in patients ...

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development. La Merie Publishing offers an e-mail notification service about the release of new products ...

Robust evidence of the clinical benefit of WINREVAIR demonstrated in the STELLAR and ZENITH studies resulted in a loss of clinical equipoise in the HYPERION ...

AUSTIN, TX, USA I January 30, 2025 I Gameto, a clinical-stage biotech company developing iPSC-based therapies for women’s health, today announced that the ...

JOURNAVX is the first and only approved non-opioid oral pain signal inhibitor and the first new class of pain medicine approved in more than 20 years -- ...

JERSEY CITY, NJ, USA I January 30, 2025 I Celltrion today announced that the U.S. Food and Drug Administration (FDA) has approved AVTOZMA® (CT-P47, ...

S-337395 is an investigational oral antiviral candidate for RSV infection that inhibits the activity of the L protein, which is essential for virus replication. 1,2 Furthermore, this drug has received ...

MUNICH, Germany I January 30, 2025 I Tubulis announced today that its second drug candidate, TUB-030, has entered clinical evaluation with successful dosing ...

SAN MATEO, CA, USA I January 29, 2025 I Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting ...